Editorial: Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 25, 2016

Editorial: Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials

partial view

In this issue of Annals of Oncology, Fujiwara and co-workers present the detailed results of health-related quality of life (QoL) of the randomized, placebo-controlled trial testing the addition of the anti-angiopoietin agent trebananib to weekly paclitaxel in patients with recurrent epithelial ovarian cancer. As detailed in the primary publication, trebananib produced a 1.6-month improvement in median progression-free survival (PFS): experimental treatment was globally well tolerated, although associated with a high incidence of oedema [1]. In this second paper, the authors show that side-effects had not a relevant QoL impact, concluding that the PFS improvement was obtained without compromising patients' QoL.
As a general rule, patient-reported outcomes and QoL results may have a great relevance in the global interpretation of the results of a clinical trial.
Even when the experimental treatment demonstrates a clinically relevant efficacy (for instance, an overall survival gain or a great prolongation of PFS), patient-reported outcomes and QoL results are still important to allow a complete picture of benefits and harms associated with treatment. By knowing details of treatment impact on QoL, clinicians and future patients in clinical practice will have a balanced description of both sides of the coin, i.e. the auspicated effect on symptoms caused by the disease (that will be …
...women with recurrent ovarian cancer receiving paclitaxel...TRINOVA-1) K. Fujiwara 1 * B. J. Monk 2 C...Correspondence to: Dr Keiichi Fujiwara, Department of Gynecologic...81-42-984-4741; E-mail: fujiwara@saitama-med.ac...women with recurrent ovarian cancer demonstrate that...


Post a Comment

Your comments?